Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL
NCT07393204
·
clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
Refractory Diffuse Large B-Cell Lymphoma
Sponsor
Andrés José Maria Ferreri